"Dystrophin Exon Skipping Oligonucleotides" in Patent Application Approval Process (USPTO 20230348909).

Předmět:	PATENT applications BECKER muscular dystrophy DUCHENNE muscular dystrophy MUSCULAR dystrophy OLIGONUCLEOTIDES FACIOSCAPULOHUMERAL muscular dystrophy
Zdroj:	Cancer Gene Therapy Week; 11/20/2023, p78-78, 1p
Abstrakt:	A patent application has been filed for dystrophin exon skipping oligonucleotides, which are being developed for the treatment of muscular dystrophy. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common forms of muscular dystrophy, and current treatments have limited efficacy. The patent application describes antisense oligonucleotides (AONs) that can be used to treat DMD by targeting a specific portion of the dystrophin gene. These AONs have potential for improving the treatment of DMD and delaying its onset. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu